LegalJun 5, 2026, 06:31 AM
Takeda revises FY2025 results due to JPY 402.5B legal provision
AI Summary
Takeda Pharmaceutical Co Ltd revised its FY2025 financial results following a jury verdict against the company in the AMITIZA antitrust litigation. The company recorded an additional provision for legal proceedings of JPY 402.5 billion and recognized related tax benefits of JPY 58.4 billion. This revision does not impact Takeda's Core financial results, the FY2025 year-end dividend, or the FY2026 financial forecast and dividend. Takeda intends to pursue post-trial motions and an appeal.
Key Highlights
- Takeda revised FY2025 financial results due to a jury verdict in the AMITIZA antitrust litigation.
- An additional provision for legal proceedings of JPY 402.5 billion was recorded.
- Related tax benefits of JPY 58.4 billion were recognized.
- The revision has no impact on Takeda's Core financial results for FY2025.
- FY2025 year-end dividend remains JPY 100 per share.
- FY2026 financial forecast and Management Guidance remain unchanged.
- FY2026 annual dividend forecast remains JPY 204 per share.
Price Impact
More from TAK